These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12087219)

  • 1. [Experience at a branch center of the National HIV Protease Inhibitor Registry].
    Franco A; Aprea L; Geraci A; Manzillo E; Pizzella T; Simioli F; Mongirulli A; Izzo CM
    Infez Med; 2001 Sep; 9(3):170-5. PubMed ID: 12087219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Another emerging event occurring during HIV infection treated with any antiretroviral therapy: frequency and role of gynecomastia.
    Manfredi R; Calza L; Chiodo F
    Infez Med; 2004 Mar; 12(1):51-9. PubMed ID: 15329529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
    Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
    HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case studies on treatment.
    Sirinek M
    Posit Aware; 1999; 10(2):29-30. PubMed ID: 11366846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution.
    Arici C; Ripamonti D; Ravasio V; Maggiolo F; Rizzi M; Finazzi MG; Suter F
    Int J STD AIDS; 2001 Sep; 12(9):573-81. PubMed ID: 11516366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
    Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor.
    Calista D; Morri M; Stagno A; Boschini A
    Am J Clin Dermatol; 2002; 3(1):59-62. PubMed ID: 11817969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
    van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
    AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunistic infections occurring during highly active antiretroviral treatment.
    Michelet C; Arvieux C; François C; Besnier JM; Rogez JP; Breux JP; Souala F; Allavena C; Raffi F; Garre M; Cartier F
    AIDS; 1998 Oct; 12(14):1815-22. PubMed ID: 9792382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
    Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
    AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity of antiretroviral therapy and implications for drug development.
    Carr A
    Nat Rev Drug Discov; 2003 Aug; 2(8):624-34. PubMed ID: 12904812
    [No Abstract]   [Full Text] [Related]  

  • 15. PI/NRTI "sparing" regimens for HIV infection. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
    Cohen C
    IAPAC Mon; 2001 Aug; 7(8):254-60. PubMed ID: 11708281
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.
    Bratt G; Karlsson A; Leandersson AC; Albert J; Wahren B; Sandström E
    AIDS; 1998 Nov; 12(16):2193-202. PubMed ID: 9833861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
    Chêne G; Binquet C; Moreau JF; Neau D; Pellegrin I; Malvy D; Ceccaldi J; Lacoste D; Dabis F
    AIDS; 1998 Dec; 12(17):2313-20. PubMed ID: 9863874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy.
    Mönkemüller KE; Call SA; Lazenby AJ; Wilcox CM
    Am J Gastroenterol; 2000 Feb; 95(2):457-62. PubMed ID: 10685750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
    Carr A; Hudson J; Chuah J; Mallal S; Law M; Hoy J; Doong N; French M; Smith D; Cooper DA;
    AIDS; 2001 Sep; 15(14):1811-22. PubMed ID: 11579243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.